EBS

Emergent Biosolutions Inc

NYSE

Add Alert

EBS

Emergent Biosolutions Inc

NYSE

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Biggiee

09/18/23 3:18 PM

Post #65

Re: #62: @Piola - Hi; I’m long for EBS. I think it

I’m starting to shift opinions on this… might be a turd of a company. There has to be something seriously rotten here for SP to plummet through 52 week lows.
GL

Biggiee

09/13/23 1:16 PM

Post #64

This has not gone the way it should.
Hmmm….

Biggiee

09/02/23 12:57 PM

Post #63

Re: #62: @Piola - Hi; I’m long for EBS. I think it

I’m sure a lot of competitors will try, but Narcan is proven, trusted and ahead of all of them. If this was a race, the $EBS horse is waaaay ahead. I’ve learned to stay clear from really long shot ideas that required a lot a praying. IMO, this is the horse to bet on, especially so near 52 week lows.
GL

Piola

09/01/23 9:21 PM

Post #62

Hi;
I’m long for EBS. I think it has great potential.
I just have a question. I’ve read that RiVive will come up with its own nasal narcan. Will this have significant impact on EBS?
Doc

Biggiee

08/31/23 10:39 AM

Post #61

Re: #60: @Biggiee - Narcan for everybody!! $EBS

18% short interest. This could run big into September when Narcan shows up in stores and gets local/national news
GL $EBS

Biggiee

08/31/23 9:40 AM

Post #60

Narcan for everybody!! $EBS

TheFinalCD PremiumMember

07/31/23 5:02 PM

Post #59

Re: #58: @LearningEveryTrade - Cali State of Emergency https://www.gov.ca.gov/2022/08/01/74502/

https://ih.advfn.com/stock-market/NYSE/emergent-biosolutions-EBS/stock-news/91689294/emergent-biosolutions-awarded-10-year-barda-contra

almost exactly 1 year later

LearningEveryTrade Free

08/01/22 9:04 PM

Post #58

Cali State of Emergency https://www.gov.ca.gov/2022/08/01/74502/

Elgordo84

05/21/22 6:23 PM

Post #57

Looks like this sleeping Giant
Is getting ready to awake!
Let’s go $EBS

InkynClyde Free

03/24/22 3:33 PM

Post #56

Building position

Cuppy

06/16/21 5:34 PM

Post #55

Re: #53: @T695 - One patient got sick out of 60,000. Buy buy buy

"Emergent was forced to halt operations at its plant in the Bayview area of Baltimore after contamination issues led to millions of spoiled vaccine doses."

https://www.nytimes.com/2021/06/16/us/emergent-biosolutions-covid-vaccine.html?action=click&module=Top%20Stories&pgtype=Homepage

since your recommendation, it has lost half its value.

T695

10/18/20 5:14 PM

Post #54

Buy buy buy

T695

10/13/20 6:59 PM

Post #53

One patient got sick out of 60,000.
Buy buy buy

T695

10/13/20 9:04 AM

Post #52

Gift

GoSlowDudes Free

08/27/20 12:02 PM

Post #51

Re: #46: @TREND1 - ……………………....EPS Mar 2020 04/30/2020 0.01

EPS

2019 $2.88
2020 $6.59
2021 $7.96

P/E = 14.70 on next years earnings. Cheap stock compared to S &P which is in the mid 20’s depending on which one you use.

Hitman970

07/31/20 11:23 PM

Post #50

Re: #49: @TREND1 - Emergent BioSolutions Signs Development and Manufacturing Agreement with

Cannon! Bull Flag Alert!!!!

TREND1

07/21/20 3:27 PM

Post #49

Re: #47: @GM26 - Don’t have the actual contract, but here’s the

Emergent BioSolutions Signs Development and Manufacturing Agreement with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Development services will begin immediately, and upon Vaxart’s election, Emergent agrees to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.

“Emergent is pleased to deploy our nimble CDMO expertise to support fellow innovators, like Vaxart, and advance an experimental COVID-19 vaccine candidate,” said Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions. “We look forward to applying our broad molecule-to-market services, including our ability to work with a multitude of delivery systems, execute under expedited timelines, and meet Vaxart’s potential need for future scalability and large-scale capacity for commercial quantities.”
Under the terms of the agreement, Emergent will provide development services out of its Gaithersburg, Md. location and manufacture drug substance at its Bayview facility in Baltimore, Md., designated a Center for Innovation in Advanced Development and Manufacturing (CIADM) by the U.S. Department of Health and Human Services. Emergent’s Bayview CIADM is the same facility used to manufacture drug substance for the company’s recently announced Novavax collaboration. The facility has the capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis, based upon the platform technology being leveraged. Additionally, it has the unique capability of producing at clinical scale, to get vaccine candidates quickly into the clinic, and in parallel, scaling up to produce commercial volumes to meet customer demand.

“I’m pleased that we are joining forces with an experienced manufacturer such as Emergent to help advance our oral COVID-19 vaccine to the clinic,” said Wouter Latour, MD, chief executive officer of Vaxart. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavor.”

About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our ability to advance potential solutions to combat coronavirus disease as well as the anticipated production level and use of the COVID-19 experimental vaccine candidate in a Phase 1 clinical study in the expected timeframe, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
statements.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com

GM26

07/21/20 3:23 PM

Post #47

Re: #44: @TREND1 - Does any one know details of VXRT contract ?

Don’t have the actual contract, but here’s the link to the PR >> https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing-0

TREND1

07/21/20 3:15 PM

Post #46

……………………....EPS
Mar 2020 04/30/2020 0.01
Dec 2019 02/20/2020 1.57
Sep 2019 11/06/2019 1.21
Jun 2019 08/01/2019 0.12

TREND1

07/21/20 1:44 PM

Post #45

EBS CHART

TREND1

07/21/20 1:41 PM

Post #44

Does any one know details of VXRT contract ?

TREND1

07/21/20 11:32 AM

Post #43

Re: #42: @TREND1 - EPS =1.03

PE Ratio = 76

TREND1

07/21/20 11:32 AM

Post #42

Re: #41: @TREND1 - Revenue = $ 1.11B

EPS =1.03

TREND1

07/21/20 11:31 AM

Post #41

Re: #40: @TREND1 - Market Cap=4.89 B

Revenue = $ 1.11B

TREND1

07/21/20 11:30 AM

Post #40

Market Cap=4.89 B

GM26

07/06/20 3:31 PM

Post #39

Re: #38: @BTCDreamer - And we know how well they're doing today! :)

Yeah I’m not sure why it’s acting this way. Should go back up once news is out on JNJ study on Vaxart oral pill soon.

BTCDreamer Free

07/06/20 3:05 PM

Post #38

Re: #36: @GM26 - And $VXRT ;)

And we know how well they're doing today! :)

mick

07/06/20 12:08 PM

Post #37

Re: #36: @GM26 - And $VXRT ;)

Emergent Biosolution (EBS)
88.45 ? 4.37 (5.20%)
Volume: 272,203 @07/06/20 11:52:45 AM EDT
Bid Ask Day's Range
- - 84.75 - 88.63
EBS Detailed Quote

GM26

07/06/20 11:55 AM

Post #36

Re: #35: @mick - PARTNER WIT $NVAX, $EBS

And $VXRT ;)

mick

05/29/20 11:45 AM

Post #35

Re: #31: @$Pistol Pete$ - $EBS Daily and Weekly Charts http://www.stockc

PARTNER WIT $NVAX, $EBS

grow fast

04/14/17 9:13 AM

Post #34

VistaTrades issued a BUY signal for EBS on 4.17.17

stocktrademan Free

07/05/16 3:44 PM

Post #33

EBS bullish 28.88

stochastics crossing up out of oversold

market overreacted to light vaccine order and may have misinterpreted
http://www.investors.com/news/technology/emergent-biosolutions-stock-plunges-on-light-anthrax-vaccine-order/?ven=YahooCP&src=AURLLED&ven=yahoo

stock usually recovers from these types of dips
low risk high reward chart

Bluesummers Free

02/24/16 8:33 PM

Post #32

An amazing company (would love to work for them some day).

Check out the Robinhood app (good for Android or IOS).

You can trade this company using that app for free.

Great way to start trading if you're new to the stock market (IMHO).

$Pistol Pete$ Free

02/18/16 9:27 PM

Post #31

$EBS Daily and Weekly Charts

$Pistol Pete$ Free

02/14/16 5:20 PM

Post #30

$EBS Daily Chart

phryne

01/22/15 1:45 PM

Post #29

I'd like to know how you checked his holdings out? I tried and failed.

ShinSekai

10/18/14 4:57 AM

Post #28

Re: #26: @Contenders - EBS in the news today.

I think I'm on to something huge. Check out Dr. Robin Robinson's recent dealings to get ahead of the curve. Their are a few more stocks poised to run up. Unfortunately a lot of the others are private. This stock, however, is one of the few that are public. Higher Monday for sure. :) I may retire before I'm 30

ShinSekai

10/18/14 4:01 AM

Post #27

Re: #26: @Contenders - EBS in the news today.

Yeah... I should've written hint hint wink wink. EBS was listed as an emergency facility in a government proposal by Dr. Robin Robinson. After some DD I figured it was only a matter of time. I hope this goes up Monday

Contenders Free

10/17/14 7:43 PM

Post #26

Re: #25: @ShinSekai - We could sure use an Ebola vaccine contender.

EBS in the news today.

Looking forward to the action next week.

http://news.yahoo.com/exclusive-u-requests-production-plans-ebola-drug-zmapp-183307513--finance.html

ShinSekai

10/17/14 1:27 AM

Post #25

We could sure use an Ebola vaccine contender.

surf1944

04/11/13 9:35 AM

Post #24

Re: #20: @surf1944 - Fisher Investments' Healthcare Picks: Large Caps Trumping Small

7:15AM Emergent BioSolutions BioSolutions announces 'positive' preclinical efficacy and PK Data for its new bispecific adaptir protein therapeutic ES414 at AACR; Treatment with ES414 showed statistically significant inhibition (EBS) 13.76 : The ES414 molecule was constructed using Emergent's ADAPTIR technology platform and selectively binds to the T cell receptor on cytotoxic T cells and Prostate Specific Membrane Antigen (PSMA), an antigen commonly found on prostate cancer cells.

Co announced the first poster, Emergent scientists described the efficacy of ES414 to prevent growth of human prostate cancer cells in vivo that express the PSMA protein on their surface: "Anti-PSMA x anti-CD3 ADAPTIR molecule inhibits tumor growth in vivo" Treatment with ES414 showed statistically significant inhibition of subcutaneous tumor outgrowth in the presence of human T cells in two independent mouse xenograft models of prostate cancer (C4-2B, MDA-PCa-2b). In both models, all treatment groups also showed a statistically significant decrease in serum PSA compared to negative controls.

Co announced The second poster described initial PK and tolerability: "Pharmacokinetic evaluation and tolerability assessment of anti-PSMA x anti-CD3 ADAPTIR molecule" These non-clinical studies showed that ES414 is pharmacologically active, has an extended serum half-life compared to antibody fragments, is well tolerated at levels well above the expected human dose, and possesses suitable characteristics for further in vivo toxicology studies.

mlkrborn

04/05/13 2:42 PM

Post #23

EBS $13.50 expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment and encouraging early clinical data (EBS) .
Emergent BioSolutions to expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment and encouraging early clinical data (EBS) 13.41 : Co announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia (CLL). The expanded protocol will include two new study cohorts to examine a lower dose of TRU-016 with rituximab in front line CLL and to evaluate the combination in relapsed CLL patients. This decision is based on strong patient enrollment along with encouraging early safety and efficacy data from this study. TRU-016 is the co's humanized anti-CD37 monospecific protein therapeutic, built on its ADAPTIRTM (Modular Protein Technology) platform, for the treatment of CLL. The co anticipates that this expanded clinical program will significantly enhance the value of TRU-016 and the company's active partnering program without impacting the company's total 2013 operating expenses.

TRU-016 is also currently being evaluated in a randomized, open label, active-controlled Phase 2 study in combination with bendamustine in patients with relapsed CLL. This study is on track to achieve its target enrollment of approximately 60 patients in April 2013.

thepostman Free

01/08/13 4:43 AM

Post #22

mlkrborn

10/03/11 3:16 PM

Post #21

EBS $17 on government contract... Rises above 52 weeks low level. Emergent BioSolutions gets $1.25B vaccine order
Emergent BioSolutions says US finalizes order of 44.8M doses of anthrax vaccine for $1.25B
ap

Related Quotes
Symbol Price Change
EBS 17.18 +1.75

On Monday October 3, 2011, 8:57 am EDT

ROCKVILLE, Md. (AP) -- Emergent BioSolutions Inc. said Monday that the U.S. government is formally ordering 44.8 million doses of the company's BioThrax anthrax vaccine in an agreement worth as much as $1.25 billion over five years.

Emergent said deliveries of the vaccine will start in 2011, with 8.5 million doses delivered in the first contract year. The company said in May that the government was planning to make the order.

Shares of Emergent BioSolutions closed at $15.43 Friday and have traded between $14.90 and $26.41 over the last 12 months.

surf1944

07/14/11 10:21 PM

Post #20

Fisher Investments' Healthcare Picks: Large Caps Trumping Small Caps

Emergent BioSolutions (EBS) is an American pharmaceutical company that developed an Anthrax vaccine and which is working on developing vaccines for Hepatitis, with a current market valuation of approximately $803 million.

http://seekingalpha.com/article/279378-fisher-investments-healthcare-picks-large-caps-trumping-small-caps?source=yahoo

stockwinner Free

07/13/10 4:57 PM

Post #19

Re: #18: @stockwinner - yeah it has been trading around this range

Emergent BioSolutions awarded $106M BioTrax contract from FDA

stockwinner Free

06/25/10 2:23 PM

Post #18

Re: #17: @mlkrborn - $15s now!

yeah it has been trading around this range for the last 2 to 3 weeks! I just jumped in today and had a very good entry point.

mlkrborn

06/25/10 2:19 PM

Post #17

Re: #16: @stockwinner - Good news so far. I think this is

$15s now!

stockwinner Free

06/25/10 2:13 PM

Post #16

Re: #15: @mlkrborn - down 1.33 to $13 'cause:

Good news so far. I think this is heading to the 20's + soon.

mlkrborn

12/08/09 10:51 AM

Post #15

down 1.33 to $13 'cause:
Shares of vaccine maker PharmAthene Inc. (PIP, $1.69, -$1.57, -48.16%) fell a day after the Department of Health and Human Services changed its approach in requesting anthrax vaccines. HHS canceled a request for proposals on recombinant protective antigen anthrax vaccine because it didn't believe vaccine developers submitting proposals could have product ready for licensure by the Food and Drug Administration within eight years.
Emergent BioSolutions Inc. (EBS, $12.52, -$1.88, -13.06%) also declined on the anthrax vaccine news, though it said the decision has no impact on its $400 million procurement contract with the Centers for Disease Control and Prevention for the delivery of 14.5 million doses of BioThrax--the only vaccine licensed by the FDA for the prevention of anthrax --into the Strategic National Stockpile.

Older

Emergent Biosolutions Inc (EBS)

Followers	7	Posters	30
Posts (Today)	0	Posts (Total)	65
Created	09/29/07	Type	Free
Moderators

Moderators' Board Intro has not been added

Most Liked Posts
(Last 30 Days)

No Liked Posts in the last 30 Days

Volume:
Day Range:
Last Trade Time:

Delayed by 15 minutes

Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Emergent Biosolutions Inc (EBS)

Most Liked Posts
(Last 30 Days)

Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Emergent Biosolutions Inc (EBS)

Most Liked Posts (Last 30 Days)

Detailed Quote

Most Liked Posts
(Last 30 Days)